| 35.37 0.26 (0.74%) | 01-26 11:08 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 43.5 | 1-year : | 50.81 |
| Resists | First : | 37.25 | Second : | 43.5 |
| Pivot price | 33.56 |
|||
| Supports | First : | 33.86 | Second : | 31.77 |
| MAs | MA(5) : | 34.79 |
MA(20) : | 33.88 |
| MA(100) : | 34.94 |
MA(250) : | 32.84 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 79.9 |
D(3) : | 75.9 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 40.71 | Low : | 23.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMCR ] has closed below upper band by 9.8%. Bollinger Bands are 23% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.58 - 35.76 | 35.76 - 35.9 |
| Low: | 34.13 - 34.33 | 34.33 - 34.5 |
| Close: | 34.81 - 35.12 | 35.12 - 35.39 |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Sun, 25 Jan 2026
UBS Maintains Immunocore(IMCR.US) With Buy Rating, Raises Target Price to $55 - 富途资讯
Sat, 24 Jan 2026
A Look At Immunocore Holdings (IMCR) Valuation As Pipeline Progress And Earnings Outlook Lift Investor Optimism - simplywall.st
Fri, 23 Jan 2026
How Immunocore Holdings Plc (IMCR) Affects Rotational Strategy Timing - Stock Traders Daily
Thu, 22 Jan 2026
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? - Nasdaq
Sat, 10 Jan 2026
How The Narrative Around Immunocore Holdings (IMCR) Is Shifting With New Data And Street Targets - Yahoo Finance
Fri, 09 Jan 2026
Immunocore (IMCR) upgraded to strong buy: Here's what you should know - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 101 (%) |
| Shares Short | 9,520 (K) |
| Shares Short P.Month | 8,560 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.86 |
| Profit Margin | -7.7 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | -1.6 % |
| Return on Equity (ttm) | -7.6 % |
| Qtrly Rev. Growth | 29.2 % |
| Gross Profit (p.s.) | 6.61 |
| Sales Per Share | 7.51 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 8 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -60.69 |
| PEG Ratio | 0 |
| Price to Book value | 4.47 |
| Price to Sales | 4.68 |
| Price to Cash Flow | 222.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|